[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Vivani Medical, Inc\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100626009",false,"NCT07430059","Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant","A Randomized, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Semaglutide Implant","SLIM-1","Inclusion Criteria:\n\n* BMI between 27 and 40 kg\u002Fm2 (inclusive)\n* HbA1c \\\u003C\u002F= 6.0% and FPG \\\u003C\u002F+ 6.7 mmil\u002FL\n* eGFR \\>\u002F= 60 mL\u002Fm2\n* No significant health issues in the opinion of the Investigator that would preclude study participation, as determined by medical history and physical examination\n\nExclusion Criteria:\n\n* Type 1 or Type 2 Diabetesa\n* A clinically significant medical condition that could potentially affect study participation and\u002For personal well-being, as judged by the Investigator\n* Treatment with glucose lowering agent(s) within 3 months before Screening","ALL","18 Years","60 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The study will evaluate the safety, tolerability and drug levels of a semaglutide implant placed just under the skin for a period of 4 weeks compared to 4 weekly injections of semaglutide (Wegovy) in overweight\u002Fobese participants who are otherwise healthy..",[27],"Obesity & Overweight",[29,30,31,32,33],"obesity","overweight","semaglutide","implant","glp-1","NOT_YET_RECRUITING","2026-06-25",{"date":37,"type":38},"2026-06-30","ACTUAL",{"date":40,"type":21},"2026-07",{"date":42,"type":21},"2027-01",{"name":44,"class":45},"Vivani Medical, Inc","INDUSTRY",""]